Core Viewpoint - The Shanghai Stock Exchange has announced the termination of the listing of Jinzhou Port Co., Ltd. due to significant violations related to false financial reporting and inflated profits over multiple years [1][2]. Group 1: Company Violations - Jinzhou Port Co., Ltd. was found to have inflated profits through false trade activities and premature recognition of port service fees from 2022 to 2024, leading to false records in its annual reports for 2022, 2023, and the first quarter of 2024 [1]. - The company also received an administrative penalty from the China Securities Regulatory Commission (CSRC) for false records in its annual reports from 2018 to 2021, indicating a pattern of misconduct over four consecutive years from 2020 to 2023 [1]. Group 2: Listing Termination Process - Following the violations, the Shanghai Stock Exchange decided to terminate the listing of Jinzhou Port Co., Ltd. based on specific provisions in the revised listing rules [1][2]. - The stock will enter a delisting preparation period of 15 trading days, with the first day having no price limits and subsequent days limited to a 10% fluctuation [2]. - The company is required to arrange for its shares to be transferred to the National Equities Exchange and Quotations system within 45 trading days after delisting [2].

星标 ★ IPO日报 精彩文章第一时间推送 6月20日晚间，锦州港股份有限公司(600190.SH，下称"*ST锦港")公告称，公司于2025年6月20 日收到上海证券交易所出具的自律监管决定书，决定终止公司股票上市。终止上市的证券种类包括 人民币普通股（A股）和境内上市外资股（B股），证券简称为*ST锦港、*ST锦港B，证券代码为 600190、900952。 AI制图 为了满足银行贷款需求，公司做大了收入和利润。2018年—2021年，公司分别虚增收入约21.2亿 元、39.47亿元、24.82亿元、0.75亿元，虚增利润0.21亿元、0.39亿元、0.44亿元、0.75亿元。 上述四年间，公司累计虚增收入约86.24亿元，累计虚增利润约1.79亿元。 整体来看，2018年—2024年，*ST锦港连续7年均在财务造假。 据IPO日报不完全统计发现，2025年以来，A股市场已有13家公司完成退市。其中，五家公司触及 面值退市、三家公司为触及市值退市、两家公司为主动申请退市、两家公司是触及重大违法强制退 市、一家公司则是被吸收合并而退市。 END 公司股票进入退市整理期的起始日为2025年6月30日，预计最后 ...

证券代码：600190/900952 证券简称：*ST 锦港/*ST 锦港 B 公告编号：2025-071 锦州港股份有限公司 关于收到上海证券交易所《关于对公司实施重大违法 强制退市相关事项的监管工作函》的公告 （〔2025〕 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 锦州港股份有限公司（以下简称"公司"）于 2025 年 5 月 29 日收到上海证 券交易所下发的《关于对公司实施重大违法强制退市相关事项的监管工作函》 $$(\bot\vdash\bot$$ 证公函【2025】0702 号），具体内容如下： "锦州港股份有限公司 定书》（〔2025〕3号），认定公司《2022年年度报告》《2023年年度报告》《2024 年第一季度报告》存在虚假记载。此外，2024年11月1日，公司公告收到中国证 监会《行政处罚决定书》(〔2024〕96 号)，认定公司2018年至2021年年度报告 虚假记载。根据《行政处罚决定书》(〔2024〕96 号)、 《行政处罚决定书》 特此公告。 锦州港股份有限公司董事会 及《上海证券交易所股 ...

Summary of Key Points Core Viewpoint - *ST Suwu (600200) is facing significant risks of forced delisting due to ongoing investigations by the China Securities Regulatory Commission (CSRC) and abnormal stock price fluctuations [1][3]. Trading Information - On May 16, *ST Suwu closed at 2.31 yuan, down 2.94%, with a turnover rate of 13.22%, trading volume of 939,500 shares, and a transaction value of 216 million yuan [1]. - The fund flow on the same day showed a net inflow of 17.62 million yuan from institutional investors, while retail investors experienced net outflows of 10.56 million yuan and 7.06 million yuan respectively [1][3]. Company Announcements - The company announced that its stock price had deviated by more than 12% over three consecutive trading days, leading to an investigation by the CSRC [1][3]. - There is a risk of forced delisting if the CSRC's findings indicate major violations of regulations [1]. - The auditing firm, Zhongxing Caiguanghua, issued an audit report for the fiscal year 2024 with a disclaimer of opinion due to non-operational fund occupation by related parties [1]. - The chairman of the company is under investigation for alleged violations of information disclosure regulations [1].

Core Viewpoint - Jinzhou Port Co., Ltd. is under investigation by the China Securities Regulatory Commission (CSRC) for suspected information disclosure violations, which may lead to significant illegal delisting of its stock due to false records in financial reports from 2020 to 2023 [1][2][3] Group 1: Investigation and Potential Delisting - The company received a notice from the CSRC regarding administrative penalties and market entry bans, indicating that its annual reports from 2020 to 2023 contain false records [1][2] - The CSRC's previous decision on November 1, 2024, confirmed that the company's annual reports from 2018 to 2021 also contained false records, leading to the current investigation [1][2] - If the company is found to have committed significant illegal acts, its stock may be terminated from listing on the Shanghai Stock Exchange [2][3] Group 2: Financial and Regulatory Risks - As of May 9, 2025, the company's stock price has been below RMB 1 for four consecutive trading days, which could trigger delisting if it continues for 20 trading days [3] - The company's audited net assets for 2024 were negative, and the financial report received a disclaimer of opinion, which may lead to financial delisting risks [3][4] - The company has been flagged for regulatory delisting risks due to significant non-operating fund occupation and failure to correct issues within the specified timeframe [5][6]

*ST锦港公告，公司因涉嫌信息披露违规，被中国证监会立案调查。2025年4月29日，公司收到中国证 监会辽宁监管局《行政处罚及市场禁入事先告知书》，查明公司2022年年度报告、2023年年度报告及 2024年第一季度报告存在虚假记载。根据《事先告知书》《决定书》所认定的事实，公司2020年至2023 年年度报告连续4年存在虚假记载，可能被实施重大违法强制退市。 ...

Group 1 - The core point of the news is that *ST Oriental (600811.SH) has been decided to be delisted by the Shanghai Stock Exchange due to serious financial misconduct, with the delisting date set for April 30, 2025 [1] - The company inflated its revenue by a total of 16.13 billion yuan and its costs by 16.073 billion yuan from 2020 to 2023, which accounted for 13.56% to 50.44% of its revenue during those periods [1] - The company has reported significant losses over the years, with net profits of -1.719 billion yuan, -996 million yuan, and -1.557 billion yuan from 2021 to 2023, totaling over 4.2 billion yuan in losses, and an expected loss of 800 million to 1.2 billion yuan in 2024 [1] Group 2 - On March 16, 2023, *ST Oriental was subjected to a major illegal forced delisting, leading to a continuous drop in stock prices after resumption of trading [2] - The chairman Zhang Hongwei was fined 10 million yuan and banned for life from the securities market, while seven other responsible individuals were fined a total of 29 million yuan [2] - As of September 30, 2022, nearly 130,000 shareholders were affected by the company's financial issues [2] Group 3 - Wu Xiaoqiu, a prominent figure in China's financial research, emphasized the need for *ST Oriental to serve as a cautionary case similar to the Enron scandal in the U.S., advocating for severe penalties against the company [4] - He called for the company to face extreme financial penalties and imprisonment for those responsible, highlighting the importance of accountability in the market [4]

Core Viewpoint - The Shenzhen Stock Exchange has decided to terminate the listing of ST Puli's stock and convertible bonds due to serious financial fraud issues, marking a significant change in the company's status in the capital market [4][5]. Financial Fraud and Consequences - ST Puli was found to have inflated its profits by a total of 669 million yuan, which accounted for 73.83% of the total reported profits for 2021 and 2022 [5][6]. - The company's core management, including the chairman and general manager, were involved in orchestrating the financial fraud, leading to severe penalties including a total fine of 24.2 million yuan and market bans for key executives [6][7]. Revenue Trends - In 2020, the company reported revenue of 1.189 billion yuan, a year-on-year increase of 25.10%, and a net profit of 407 million yuan, up 35.30% [6]. - Revenue continued to grow in 2021, reaching 1.509 billion yuan (up 26.94%), but net profit only slightly increased to 417 million yuan (up 2.25%) [6]. - In 2022, revenue rose to 1.619 billion yuan (up 7.31%), but net profit fell significantly to 295 million yuan, a decrease of 29.20% [6][7]. - By 2023, revenue dropped to 1.304 billion yuan, a decline of 19.43%, with net profit plummeting to 85.92 million yuan, down 70.87% [7]. Product Performance - The company's major products, particularly cardiovascular drugs, allergy medications, antibiotics, and digestive drugs, experienced significant revenue declines in 2023 [7]. - The overall business environment for ST Puli is deteriorating, with challenges expected to intensify in 2024, despite some products showing temporary growth [7]. Market Implications - The termination of ST Puli's listing serves as a warning to the pharmaceutical industry about the importance of compliance and maintaining core competitiveness to gain market trust [7].

星标 ★ IPO日报 精彩文章第一时间推送 4月18日晚间，海南普利制药股份有限公司（300630.SZ，以下简称"*ST普利"或"普利制药"）发布公告，公司于2025年4月18日收到深交 所《关于海南普利制药股份有限公司股票及可转换公司债券终止上市的决定》。深圳证券交易所决定终止公司股票及可转债上市。 公司股票及可转债进入退市整理期的起始日为2025年4月28日，退市整理期为十五个交易日，预计最后交易日期为2025年5月21日。 制图：佘诗婕 虚增利润近7亿 今年3月，上市公司发布公告称，收到证监会行政处罚决定书。 2021年至2022年，普利制药通过虚构成品药和原料药销售业务的方式，虚假确认药品销售收入和利润。 其中，2021年多计营业收入 436004495.01元，占当年披露营业收入的28.90%，对应营业成本128197101.98元，多计利润总额290175562.61元，占当年披露利润 总额的 62.06% ；2022年多计营业收入455776233.78元，占当年披露营业收入的25.23%，对应营业成本69013203.17元，多计利润总 额 379066467.07元，占当年披露利润总额的8 ...

| 项目 | 本报告期 | 上年同期 | | --- | --- | --- | | 归属于上市公司 股东的净利润 | 亏损:43,200 万元-53,700 万元 | 亏损:67,278 万元 | | 扣除非经常性损 益后的净利润 | 亏损:46,921 万元-57,421 万元 | 亏损:70.133 万元 | | 营业收入 | 72,500 万元一81,500 万元 | 55,679 万元 | | 扣除后营业收入 | 71,500 万元-80,500 万元 | 54,380 万元 | 东方通称，2024年度公司持续推进市场拓展工作，同时降本增效初见成效，报告期亏损同比收窄约 20%-36%；若不考虑商誉减值计提因素，公司亏损收窄金额预计为1.74亿元至 2.09亿元，较上年同期亏 损收窄约60%-72%。 值得注意的是，2022年和2023年，东方通实现归属净利润分别约为-3936.65万元、-6.73亿元。 截至4月14日收盘，东方通报14.99元每股，收涨1.42%，总市值83.63亿元。 （文章来源：新华财经） 东方通称，若后续经中国证监会行政处罚认定的事实，触及《深圳证券交易所创业板股票上市规则 ...